Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
F 14.21 -0.21% -0.03
CHRS closed up 2.74 percent on Thursday, April 15, 2021, on 79 percent of normal volume.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical CHRS trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness -0.21%
180 Bearish Setup Bearish Swing Setup 2.53%
Slingshot Bearish Bearish Swing Setup 2.53%
MACD Bullish Signal Line Cross Bullish 2.53%
Oversold Stochastic Weakness 2.53%
New Downtrend Bearish 2.08%
New 52 Week Low Weakness 2.08%
Oversold Stochastic Weakness 2.08%
New 52 Week Closing Low Bearish 3.72%
New 52 Week Low Weakness 3.72%
Older End-of-Day Signals for CHRS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 4 hours ago
20 DMA Resistance about 4 hours ago
Up 1% about 4 hours ago
Up 3% 1 day ago
60 Minute Opening Range Breakout 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coherus BioSciences, Inc. Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Treatment Of Breast Cancer Chemotherapy Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Neutropenia Etanercept

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.2166
52 Week Low 13.53
Average Volume 1,151,073
200-Day Moving Average 17.62
50-Day Moving Average 15.89
20-Day Moving Average 14.49
10-Day Moving Average 14.10
Average True Range 0.61
ADX 25.53
+DI 14.29
-DI 21.43
Chandelier Exit (Long, 3 ATRs ) 14.38
Chandelier Exit (Short, 3 ATRs ) 15.35
Upper Bollinger Band 15.54
Lower Bollinger Band 13.43
Percent B (%b) 0.38
BandWidth 14.59
MACD Line -0.55
MACD Signal Line -0.59
MACD Histogram 0.0389
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 72 Million
EPS 2.05
Price-to-Earnings (P/E) Ratio 6.94
Price-to-Sales 2.95
Price-to-Book 5.09
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.87
Resistance 3 (R3) 14.83 14.59 14.77
Resistance 2 (R2) 14.59 14.43 14.61 14.73
Resistance 1 (R1) 14.41 14.33 14.50 14.45 14.69
Pivot Point 14.17 14.17 14.21 14.19 14.17
Support 1 (S1) 13.99 14.01 14.08 14.03 13.79
Support 2 (S2) 13.75 13.91 13.77 13.75
Support 3 (S3) 13.57 13.75 13.72
Support 4 (S4) 13.61